Silke Roedder, Pharm.D., Ph.D.
- Assistant Research Scientist
Contact Information
Education
School of Pharmacy, University of Bonn, Germany, Pharm.D. 2000-2004
School of Natural Sciences, Swiss Federal Institute of Technology (ETHZ), Zürich, Switzerland, 2003
University of Bern, Graduate School for Cellular and Biomedical Sciences, Bern, Switzerland, Ph.D., 2006-2009
Biography
Dr. Silke Roedder has been working in human biomarker research for 8 years, with a strong focus on the development of non-invasive molecular markers for the diagnosis and prediction, as well as for individual patient monitoring, and repositioning of FDA approved drugs in the field of Solid Organ Transplantation and Immunology.
As Pharmacist with a Ph.D. in Biomedical Sciences, Dr. Roedder is highly skilled in translational research, including hands-on in-silico (QPCR, Microarray, ELISA, Western Blot, Zymography, Laser Capture Microdissection), in-vitro (cell-culture, cell assays), and in-vivo (animal models of organ rejection) Experiments, the Analysis of high- and low-throughput genomic and proteomic Data including the development of statistical algorithm for classification, in writing of Grants, Original- and Review Articles for Publication. In addition to Study and experimental design, Management of Personnel, interdisciplinary, international and national collaborations, written and oral communication at national and international meetings and seminars.
Dr. Roedder has published 13 original articles in PubMed, including 2 invited Reviews, 25 Abstracts at international and national Meetings, and is Co-Author of a Patent Application for non-invasive markers in Preeclampsia. Dr. Roedder also regularly reviews articles for AJT and PlosOne and she is an active meeting of 5 professional Organizations.
In the News
- Sarwal Lab - December 01, 2014UCSF News reports on research led by Minnie Sarwal, MD, PhD, Director of the Sarwal Lab, in developing a test for diagnosing and predicting acute rejection (AR) in kidney transplants, a finding that eventually could replace the need for biopsies and lead to earlier detection of AR and treatment. 'We have found a set of genes in blood that pick up inflammation and acute rejection in different solid organ transplants and thus can replace the need for an invasive biopsy in the future,' said [...]
